The second axis of Clinical Hemostatic Material segmentation is application, which partitions the market into cardiovascular surgery, neurosurgery, orthopedic surgery, and general surgery. Cardiovascular procedures—encompassing coronary artery bypass grafting, valve repair, and peripheral bypass—capture the largest slice, approximately 35 % of revenue, because rapid hemostasis is critical to prevent peri‑operative bleeding and downstream ischemic events. Neurosurgical use, accounting for about 25 %, relies on high‑precision agents such as flowable fibrin glues to manage delicate brain and spinal cord tissue. Orthopedic interventions, representing roughly 20 %, benefit from bone‑compatible hemostats that support implant fixation and reduce postoperative hematoma. The remaining 20 % pertains to general surgery, including gastrointestinal, hepatic, and trauma operations, where versatile, easy‑to‑apply materials are preferred. Growth in each application is driven by procedure volume, regulatory acceptance, and cost‑effectiveness analyses; cardiovascular and neurosurgical segments exhibit the highest compound annual growth rates (6–8 %), while orthopedic and general surgery maintain steady double‑digit volume expansions. This application‑focused taxonomy clarifies demand drivers across the Clinical Hemostatic Material market.
